How to Transition from MDD to MDR? 5 Core Steps

European Union Medical Device Regulation (EU MDR) has replaced the previous Medical Device Directive (MDD). It aims to address gaps in oversight and improve patient safety. EU MDR introduces stricter requirements for clinical evaluation, post-market surveillance, traceability through UDI, and transparency via the EUDAMED database. In this blog, we have provided a detailed guide on how to transition from MDD to MDR. Additionally, we have highlighted the deadline for transition for different devices.

Why was the EU MDD no longer enough?

The Medical Device Directive (MDD) was no longer sufficient because it was designed in the 1990s for a far less complex medical technology landscape. Moreover, it lacked the rigor needed to address modern innovations, patient safety concerns, and transparency demands. It allowed broad use of equivalence claims instead of requiring device-specific clinical evidence, had weaker post-market surveillance obligations, and did not adequately regulate emerging areas, such as SaMD or implantable technologies. As a result, the EU introduced the EU Medical Device Regulation (MDR) to strengthen clinical evaluation, enforce traceability through UDI and EUDAMED, increase oversight of Notified Bodies, and harmonize rules across member states. This ensured higher patient safety and restored public trust in the CE marking system.

Transition from MDD to MDR: 8 major changes

1. Device classification: MDR introduces stricter and more detailed classification rules, especially for software, implantables, and reusable surgical instruments. Many devices that were lower risk under MDD are now reclassified into higher risk categories, thereby requiring more rigorous conformity assessments.
2. Clinical evidence: Under MDR, manufacturers must provide device-specific clinical data rather than relying on equivalence claims. This ensures that safety and performance are demonstrated directly for the device being marketed.
3. Post-Market Surveillance (PMS): MDR mandates proactive and continuous PMS systems, including periodic safety update reports (PSURs) for higher-risk devices. This shifts the focus from reactive reporting to ongoing monitoring of device performance and safety.
4. Unique Device Identification (UDI): MDR requires implementation of UDI for all devices to improve traceability across the supply chain. This system enhances recall efficiency and strengthens patient safety.
5. EUDAMED database MDR establishes EUDAMED as a centralized EU database for device registration, vigilance, and market surveillance. It increases transparency by making key safety and performance information publicly accessible.
6. Notified body oversight: MDR imposes stricter designation and monitoring of Notified Bodies, thereby ensuring higher competence and consistency. Manufacturers face more rigorous audits and technical documentation reviews.
7. Transparency and public access: MDR requires publication of a Summary of Safety and Clinical Performance (SSCP) for Class III and implantable devices. This empowers healthcare professionals and patients with accessible safety data.
8. Expanded scope: MDR explicitly covers products without a medical purpose but with similar risk profile, such as cosmetic contact lenses and aesthetic implants. Thus, transition from MDD to MDR closes regulatory gaps left under MDD.

Major deadlines for transition from MDD to MDR

Device Category	Deadline for MDR Compliance	Notes / Legacy Conditions
Class I (non-sterile, no measuring, not reusable surgical instruments)	May 26, 2021	Already required MDR compliance. No extension for legacy devices.
Legacy Class I (sterile, measuring, reusable surgical instruments)	Dec 31, 2028	Must transition to MDR. Certificates under MDD remain valid until expiry but no later than Dec 31, 2028.
Class III custom-made implantable devices	May 26, 2026	Legacy certificates valid until this date. Requires MDR-compliant QMS and NB application by May 26, 2024.
Class III devices & Class IIb implantables; except Well-Established Technologies (WET)	Dec 31, 2027	Legacy CE certificates valid until this date. Sell-off allowed until Dec 31, 2028.
Class IIb (non-implantable), Class IIa, Class Is/Im/Ir	Dec 31, 2028	Legacy CE certificates valid until this date. Includes sterile/measuring Class I.
Well-Established Technologies (WET) devices (sutures, staples, dental fillings, braces, crowns, screws, wedges, plates, wires, pins, clips, connectors)	Dec 31, 2028	Special extension granted due to lower risk profile.
Certificates issued under MDD/AIMDD before May 26, 2021	Valid until expiry date but no later than Dec 31, 2027/2028 depending on class	Legacy devices can remain on market if no significant changes in design/intended use and MDR QMS obligations are met.

MDD to MDR gap analysis checklist

We have provided a gap analysis checklist for a smooth transition from MDD to MDR.

1. Device classification

MDR introduces stricter rules that often push devices into higher risk categories compared to MDD. This means manufacturers must reassess each product under Annex VIII.

2. Technical documentation

MDR requires far more comprehensive technical files than MDD, covering design, risk management, PMS, and clinical evaluation in detail. Manufacturers must update labeling, IFUs, and ensure traceability through UDI integration.

3. Clinical evidence

Under MDD, equivalence claims were often sufficient. However, MDR demands device-specific clinical data. This requires new or updated clinical investigations to prove safety and performance. For Class III and implantable devices, a Summary of Safety and Clinical Performance (SSCP) must be published in EUDAMED.

4. Quality management system (QMS)

MDR requires QMS alignment with ISO 13485:2016. Additionally, integration of MDR-specific obligations is required. Risk management (ISO 14971) must be embedded into the system. Supplier controls, CAPA, and audit readiness are now critical for demonstrating compliance.

5. Post-market surveillance (PMS) and vigilance

MDD’s reactive PMS approach is replaced by MDR’s proactive, continuous monitoring. Manufacturers must prepare PMS plans, PSURs, and trend reporting for higher-risk devices. Vigilance reporting timelines are stricter, requiring faster and more transparent communication of incidents.

6. UDI and EUDAMED

MDR introduces Unique Device Identification (UDI) for all devices, thereby ensuring traceability across the supply chain. Manufacturers must register devices, certificates, and vigilance data in EUDAMED’s six modules. This enhances transparency, recall efficiency, and public access to safety information.

7. Notified body engagement

MDR imposes stricter designation and monitoring of Notified Bodies. Early engagement is critical due to capacity bottlenecks and longer review timelines.

8. Legacy devices

Devices CE-marked under MDD before May 26, 2021 can remain on the market under transitional provisions. However, they must comply with MDR QMS, PMS, and vigilance obligations during the transition. Certificates remain valid until expiry but no later than Dec 31, 2027/2028 depending on device class.

5 pro tips for smooth transition from MDD to MDR

1. Conduct a gap analysis: Begin by comparing your existing MDD documentation, processes, and certifications against MDR requirements. This helps identify missing elements, such as clinical data, PMS plans, and UDI readiness. A structured gap analysis ensures you prioritize resources where compliance gaps are most critical.
2. Reclassify devices under MDR rules: MDR Annex VIII introduces stricter classification criteria, especially for software, implantables, and reusable surgical instruments. Many devices are now in higher risk categories, thereby requiring more rigorous conformity assessments.
3. Upgrade your quality management system (QMS): Align your QMS with ISO 13485:2016 and MDR-specific requirements, including risk management (ISO 14971) and PMS obligations. This means integrating proactive surveillance, vigilance reporting, and continuous improvement loops. A robust QMS is essential to demonstrate compliance during Notified Body audits.
4. Strengthen clinical evidence: Under MDR, reliance on equivalence claims is no longer sufficient. Now, device-specific clinical data is mandatory. Manufacturers must conduct or update clinical investigations to prove safety and performance. For Class III and implantable devices, a Summary of Safety and Clinical Performance (SSCP) must be published in EUDAMED.
5. Implement UDI and EUDAMED registration: MDR requires Unique Device Identification (UDI) for traceability across the supply chain. Devices, certificates, and vigilance data must be registered in EUDAMED’s six interconnected modules. This enhances transparency, recall efficiency, and public access to safety information.

Pharmadocx Consultants offers dedicated CE marking support under EU MDR covering device classification, MDD-MDR gap analysis, technical documentation and clinical evaluation report preparation, and notified body coordination. Email at [email protected] or call/Whatsapp on 9996859227 for a smooth transition from MDD to MDR.